Use of chemotherapy at the end of life among Taiwanese cancer decedents, 2001–2006
- 27 January 2012
- journal article
- research article
- Published by Informa UK Limited in Acta Oncologica
- Vol. 51 (4), 505-511
- https://doi.org/10.3109/0284186x.2011.653440
Abstract
[[abstract]]Introduction. The availability of new chemotherapeutic agents has lengthened the treatment timeline for advanced cancers and increases the likelihood of receiving chemotherapy near death. Use of chemotherapy near the end of life may not benefit cancer patients. However, no population-based study has examined the determinants for continuing chemotherapy at the end of life for all ages and cancer groups as well as for a whole country. This population-based study assessed the association between continuation of chemotherapy in the last month of life and patient demographics, disease characteristics, primary physician's specialty, hospital characteristics, and healthcare resource availability at the hospital and regional levels. Materials and methods. Retrospective population-based cohort study using administrative data among 204 850 Taiwanese cancer decedents in 2001-2006. Results. Rates of continued chemotherapy in the last month of life for each study year were 17.5%, 17.4%, 17.3%, 19.0%, 20.0%, and 21.0%, respectively and have remained steady since 2001. Taiwanese cancer patients had greater odds for continuation of chemotherapy in the last month of life if they were male [adjusted odds ratio (AOR) 1.19, 95% confidence interval (CI) 1.13-1.25], younger, single [1.21 (1.09-1.35)], had lower comorbidity levels, were diagnosed with hematologic malignancies [1.90 (1.09-1.35)] and breast cancer [1.24 (1.08-1.43)], had metastatic disease [1.36 (1.27-1.46)], and survived < 1 year but longer than two months post-diagnosis. The odds for continued chemotherapy in patients' last month was significantly increased by being cared for by a medical oncologist [3.49 (3.04-3.99)] or in a teaching hospital [1.39 (1.11-1.74)] and with the highest intensity of total inpatient hospital beds [1.63 (0.99-2.68)], but was not influenced by regional healthcare resources (total hospital and hospice beds). Conclusion. The relative risk for continuation of chemotherapy in the last month of life was determined by patient demographics and disease characteristics, physician specialty, and healthcare resources at the primary hospital levelKeywords
This publication has 32 references indexed in Scilit:
- End‐of‐life care for older cancer patients in the Veterans Health Administration versus the private sectorCancer, 2010
- Comparison of Prospective and Retrospective Indicators of the Quality of End-of-Life Cancer CareJournal of Clinical Oncology, 2008
- Aggressiveness of Cancer Care Near the End of Life: Is It a Quality-of-Care Issue?Journal of Clinical Oncology, 2008
- Aggressiveness of care in a prospective cohort of patients with advanced NSCLCCancer, 2008
- Aggressiveness of Cancer-Care near the End-of-Life in KoreaJapanese Journal of Clinical Oncology, 2008
- End-of-Life Care in Lung Cancer Patients in Ontario: Aggressiveness of Care in the Population and a Description of Hospital AdmissionsJournal of Pain and Symptom Management, 2008
- Trends in End-of-Life ICU Use Among Older Adults With Advanced Lung CancerChest, 2008
- Use of chemotherapy at the end of life in a Portuguese oncology centerSupportive Care in Cancer, 2007
- Trends in the Aggressiveness of Cancer Care Near the End of LifeJournal of Clinical Oncology, 2004
- Identifying Potential Indicators of the Quality of End-of-Life Cancer Care From Administrative DataJournal of Clinical Oncology, 2003